source
- Teva's experimental antibody cuts intestinal damage in celiac patients after gluten challengeTeva reported that a single injection of an experimental antibody markedly lowered intestinal damage in participants with celiac disease who continued to consume gluten daily. The study was a glut…
- Fortrea acquires Worldwide Clinical Trials' early-phase division for $45 millionFortrea announced it will purchase the early-phase services division of Worldwide Clinical Trials for $45 million. The transaction gives Fortrea control of Worldwide's clinical pharmacology unit,…